Weekly Research Analysts’ Ratings Updates for Compass Pathways (CMPS)

by · The Cerbat Gem

Compass Pathways (NASDAQ: CMPS) recently received a number of ratings updates from brokerages and research firms:

  • 5/22/2026 – Compass Pathways had its “buy” rating reaffirmed by Raymond James Financial, Inc..
  • 5/22/2026 – Compass Pathways had its “buy” rating reaffirmed by HC Wainwright.
  • 5/22/2026 – Compass Pathways is now covered by Wolfe Research. They set an “outperform” rating on the stock.
  • 5/16/2026 – Compass Pathways was upgraded by Wall Street Zen from “strong sell” to “hold”.
  • 5/15/2026 – Compass Pathways had its price target raised by Maxim Group from $12.00 to $20.00. They now have a “buy” rating on the stock.
  • 5/14/2026 – Compass Pathways had its price target raised by Morgan Stanley from $16.00 to $17.00. They now have an “overweight” rating on the stock.
  • 5/14/2026 – Compass Pathways had its price target raised by Royal Bank Of Canada from $21.00 to $22.00. They now have an “outperform” rating on the stock.
  • 5/13/2026 – Compass Pathways had its “buy” rating reaffirmed by BTIG Research. They now have a $14.00 price target on the stock.
  • 5/7/2026 – Compass Pathways was given a new $18.00 price target by UBS Group AG.
  • 5/5/2026 – Compass Pathways was upgraded by Jefferies Financial Group Inc. to “strong-buy”.
  • 5/3/2026 – Compass Pathways is now covered by Jefferies Financial Group Inc.. They set a “buy” rating and a $18.00 price target on the stock.
  • 4/28/2026 – Compass Pathways had its “buy” rating reaffirmed by HC Wainwright. They now have a $70.00 price target on the stock.
  • 4/24/2026 – Compass Pathways was given a new $17.00 price target by UBS Group AG.
  • 4/24/2026 – Compass Pathways is now covered by B. Riley Financial, Inc.. They set a “buy” rating and a $17.00 price target on the stock.
  • 4/20/2026 – Compass Pathways had its “sell (d-)” rating reaffirmed by Weiss Ratings.
  • 4/20/2026 – Compass Pathways had its “buy” rating reaffirmed by BTIG Research. They now have a $14.00 price target on the stock.

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.

Featured Stories